What is CNS Pharmaceuticals, Inc. (CNSP) stock price today?

CNS Pharmaceuticals, Inc. (CNSP) is currently trading at $5.35, up 0% today.

What is CNSP P/E ratio?

CNS Pharmaceuticals, Inc.'s P/E ratio is -0.23. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CNSP return on equity (ROE)?

CNS Pharmaceuticals, Inc.'s return on equity (ROE) is -204.25%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CNS Pharmaceuticals, Inc.'s market cap?

CNS Pharmaceuticals, Inc. has a market capitalization of $7.82M.

NASDAQ · Biotechnology

CNS Pharmaceuticals, Inc. (CNSP) Stock

$5.35 +0.00% NASDAQ: CNSP Healthcare

Valuation

Metric	Value
Price	$5.35
Market Cap	$7.82M
P/E Ratio	-0.23
P/B Ratio	2.00
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$10.59
52-Week Low	$1.90
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-204.25%
ROA	-76.12%
ROCE	-92.94%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	2.00

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-14.0M	$-15.0M	$-19.0M	$-15.0M	$-16.0M
Net Profit	$-14.0M	$-15.0M	$-19.0M	$-15.0M	$-16.0M
EPS	$-495027.00	$-336499.00	$-150114.00	$-466.44	$-35.75
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$9.0M	$13.0M	$2.0M	$9.0M	$9.0M
Total Liabilities	$2.0M	$5.0M	$6.0M	$3.0M	$4.0M
Cash	$5.0M	$10.0M	$1.0M	$6.0M	$7.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment ACCESS Newswire · Jun 8, 2026 CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress ACCESS Newswire · May 20, 2026 CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders MT Newswires · May 19, 2026 Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6 24/7 Wall St. · May 14, 2026 CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress ACCESS Newswire · May 14, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-14.0M	$-11.0M	$-14.0M	$-17.0M	$-14.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$3.0M	$0	$1.0M
Net Cash Flow	$-9.0M	$5.0M	$-10.0M	$6.0M	$1.0M
Free Cash Flow	$-14.0M	$-11.0M	$-14.0M	$-17.0M	$-14.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.73
FCF Yield	-172.73%
Quick Ratio	5.86
Interest Coverage	-1131.57
Return 1Y	-54.97%
Return 3Y	-99.99%
Return 5Y	-100.00%

Ownership

Insiders Held0.49%

Institutions Held12.51%

Institutions Float Held12.57%

Institutional Holder	Shares	Report Date
Stonepine Capital Management, LLC	61,000	2026-03-31
Ikarian Capital, LLC	45,830	2026-03-31
Geode Capital Management, LLC	23,189	2026-03-31
Boothbay Fund Management, LLC	13,524	2026-03-31
Tower Research Capital LLC (TRC)	1,310	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CMNDClearmind Medicine Inc.	$6.58	-0.30%	-0.51	$1.22M	0.00%
ENSCEnsysce Biosciences, Inc.	$0.53	+15.07%	-0.16	$8.10M	0.00%
GRIGRI Bio, Inc.	$1.74	+3.57%	-0.04	$3.80M	0.00%
KTTAPasithea Therapeutics Corp.	$0.47	+6.03%	-0.19	$15.62M	0.00%
NLSPNLS Pharmaceutics AG	$2.91	-12.61%	-0.43	$919601	0.00%

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is led by CEO Rami Levin, employs 4 people, headquartered in US, publicly traded since 2019.

CNS Pharmaceuticals, Inc. (CNSP) stock trades at $5.35 with a market capitalization of $7.82M. The stock is valued at a price-to-earnings (P/E) ratio of -0.23, price-to-book of 2.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.90 and $10.59, and currently trades 49.5% below its 52-week high.

On profitability, CNS Pharmaceuticals, Inc. generates a return on equity (ROE) of -204.25%, return on capital employed of -92.94%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides